on Onco-Innovations Limited (isin : CA68237C1059)
Onco-Innovations Advances with Manufacturing for PNKP Inhibitor
Onco-Innovations Limited has announced that Dalton Pharma Services has begun manufacturing material for preclinical testing of their PNKP inhibitor technology. This marks a move from early research to production scale-up. The material, crucial for future clinical trials, will support Onco's upcoming Investigational New Drug (IND) submission in the US.
The PNKP inhibitor, A83B4C63, showed promising results in University of Alberta studies, significantly extending survival in colorectal cancer models. Dalton, a respected Canadian CDMO, offers vital expertise for this phase. The partnership aims to enhance Onco's development trajectory towards potential therapeutic applications in oncology.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Onco-Innovations Limited news